AVTE - Aerovate Therapeutics GAAP EPS of -$0.45 misses by $0.17

Aerovate Therapeutics press release (NASDAQ:AVTE): Q1 GAAP EPS of -$0.45 misses by $0.17. Cash, cash equivalents and short-term investments of $161.1M. The company is reiterating strong financial position funding operations into the second half of 2025. The company expects to report topline data from the Phase 2b portion of the IMPAHCT trial in the fourth quarter of 2023 or first quarter of 2024. "We expect that our cash, cash equivalents and short-term investments will be sufficient to fund our operations into the second half of 2025, based on our current operating plan."

For further details see:

Aerovate Therapeutics GAAP EPS of -$0.45 misses by $0.17